India RNA Therapeutics Market By Product (Vaccines, Drugs), By Type (mRNA Therapeutics, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotide (ASO) Therapeutics, Others), By Indication (Infectious Diseases, Rare Genetic Diseases/Hereditary Diseases, Other), By End User (Hospitals and Clinics, Research Settings), By Region and Competition, Forecast & Opportunities, 2020-2030F

Market Overview

India RNA Therapeutics Market was valued at USD 48.91 Million in 2024 and is expected to reach USD 70.45 Million by 2030 with a CAGR of 6.23% during the forecast period.

The RNA therapeutics market in India is rapidly gaining traction, fueled by advances in biotechnology, rising cases of genetic and chronic diseases, and the proven success of mRNA vaccines during the COVID-19 pandemic. With a growing emphasis on personalized medicine, RNA-based treatments are emerging as effective solutions for cancer, cardiovascular conditions, and rare genetic disorders. Strong R&D investments, a supportive regulatory landscape, and cost-efficient manufacturing capabilities especially in hubs like Maharashtra and Gujarat are strengthening market growth. Collaborations between Indian and global biopharma companies are further accelerating innovation and commercialization.

Despite this progress, challenges remain. High development costs, limited domestic expertise in advanced RNA technologies, and infrastructure gaps in smaller cities pose barriers. Ensuring affordability and accessibility for India’s large population is another key concern. Additionally, competition from conventional therapies and complex regulatory pathways for novel biologics may slow adoption. Nevertheless, increasing demand for precision medicine and India’s established pharmaceutical ecosystem position the RNA therapeutics market for strong future expansion..

Key Market Drivers

Growing Prevalence of Genetic and Chronic Diseases

The increasing prevalence of genetic and chronic diseases in India is a key driver for the RNA Therapeutics Market. Genetic disorders, such as rare diseases, congenital malformations, and enzyme deficiencies, pose significant challenges to India’s healthcare system, necessitating advanced therapeutic solutions like RNA-based treatments. The substantial burden of rare and inherited diseases highlights the need for personalized medicine, particularly as traditional treatment approaches fail to address the underlying genetic causes effectively. Approximately 70 million individuals in India are affected by known rare diseases, accounting for about one-fifth of the global rare disease population. Moreover, annually, around 500,000 infants are born with congenital malformations, 400,000 with glucose-6-phosphate dehydrogenase (G6PD) deficiency, and 10,000 with amino acid disorders in India.

Chronic diseases further exacerbate India’s healthcare challenges, driving demand for innovative treatments. Cardiovascular diseases (CVDs) remain a leading cause of mortality, with India facing a higher CVD burden than the global average. Similarly, the rapid rise in diabetes prevalence emphasizes the urgent need for advanced therapeutics to manage and mitigate disease progression. RNA therapeutics offer significant promise in tackling such chronic conditions by targeting disease pathways more precisely than conventional therapies. The age-standardized CVD death rate in India is 272 per 100,000 population, significantly higher than the global average of 235 per 100,000 population. Moreover, according to the ICMR INDIAB study (2023), the prevalence of diabetes in India has reached 10.1 crores, placing immense pressure on the healthcare system.

This growing burden of genetic and chronic diseases underscores the critical need for RNA-based therapeutics, which can revolutionize the treatment landscape by offering targeted, efficient, and personalized solutions.

Rising Government and Private Sector Investments

Rising government and private sector investments are becoming a central force behind the expansion of India’s RNA therapeutics landscape, as public funding, policy support, and industry capital are helping move the sector from early research toward scalable development and commercialization. Government-backed institutions such as the Department of Biotechnology and BIRAC are strengthening domestic capabilities through mission-led support for mRNA platforms, clinical development, and biomanufacturing, while also encouraging partnerships that reduce dependence on imported technologies.

This momentum is being reinforced by private biopharma companies that are investing in research, manufacturing scale-up, and global alliances across mRNA vaccines, self-amplifying RNA platforms, RNA interference, and other precision biotherapeutic approaches. The post-pandemic environment has further accelerated interest in RNA science, with biotech hubs in states such as Maharashtra and Gujarat benefiting from India’s cost-effective manufacturing base and a more supportive innovation ecosystem. For Instance, CEPI committed up to 13.38 million dollars to Gennova Biopharmaceuticals in 2025 for a self-amplifying mRNA vaccine against Nipah virus, building on its earlier commitment of up to 3.6 million dollars in 2023, while Gennova’s earlier mRNA vaccine program had already received support from DBT under the Ind CEPI mission and Mission COVID Suraksha implemented by BIRAC.

Download Free Sample Report

Key Market Challenges

Regulatory and Clinical Challenges

Regulatory and clinical challenges remain a major constraint on India’s RNA therapeutics market because companies developing mRNA vaccines, RNA interference therapies, and antisense oligonucleotides must navigate a multi-layered approval process that is still evolving and not yet fully tailored to the specific scientific and delivery complexities of RNA-based products. Unlike conventional drugs, RNA therapeutics often require novel delivery systems, advanced stability controls, and more specialized manufacturing oversight, which can create uncertainty when existing regulatory pathways are applied to products with fundamentally different mechanisms of action.

Large-scale clinical trials add another layer of difficulty, as sponsors must manage India’s population diversity, build robust site infrastructure, ensure high-quality cold-chain and trial operations, and maintain compliance with global standards for safety, efficacy, and manufacturing quality, all of which increase cost and execution risk. These burdens are particularly heavy for smaller biotech firms and startups, which may have strong scientific platforms but limited regulatory bandwidth and capital to keep pace with shifting international expectations. For Instance, India’s first mRNA COVID-19 vaccine candidate by Gennova enrolled only 82 participants across three Phase I trial sites before receiving approval to move into a multicentre Phase II and Phase III study, illustrating how RNA products must advance through carefully staged and resource-intensive regulatory and clinical milestones before commercialization.

Key Market Trends

Advancements in Biotechnology and Genomics

Rapid advances in biotechnology and genomics are pushing India’s RNA therapeutics landscape toward more precise and clinically relevant innovation, as deeper insight into gene expression, molecular pathways, and disease biology is helping researchers design RNA-based interventions for cancers, rare genetic disorders, and chronic illnesses with greater target specificity. Technologies such as next-generation sequencing, CRISPR-Cas9, and synthetic biology are accelerating this shift by enabling faster identification of actionable mutations and therapeutic targets, which is especially important in a market that is increasingly aligning with personalized medicine.

The momentum created by mRNA technology during the pandemic has further strengthened confidence in RNA platforms, while falling sequencing costs and wider access to genomic data are encouraging the development of therapies better suited to Indian patient populations rather than relying only on imported innovation pathways. Progress in delivery science, including nano-lipid and related carrier systems, is also improving stability, manufacturability, and scalability, making RNA products more deployable across real-world healthcare settings in India. For Instance, MedGenome stated in 2024 that it has conducted over 600,000 genetic tests, sequenced more than 350,000 exomes and genomes, and works with over 5,500 hospitals and 15,000 clinicians across India, highlighting how expanding genomics infrastructure is strengthening the scientific foundation needed for RNA-based therapeutic development.

Segmental Insights

Type Insights

Based on Type, mRNA Therapeutics have emerged as the fastest growing segment in the India RNA Therapeutics Market in 2024. This is due to its transformative potential, versatility, and wide-ranging applications. The success of mRNA vaccines, particularly during the COVID-19 pandemic, has underscored the technology's ability to deliver rapid, effective, and scalable solutions for global health challenges. This has not only accelerated interest and investments in mRNA research but also validated its potential to address a variety of diseases beyond infectious ones, such as cancer, rare genetic disorders, and autoimmune conditions.

A key factor driving the growth of mRNA therapeutics is its relatively straightforward and cost-effective manufacturing process compared to traditional biologics. Unlike other RNA-based technologies, mRNA therapeutics can be synthesized in a laboratory without the need for complex cell cultures, enabling faster development timelines. Additionally, advancements in delivery systems, such as lipid nanoparticles, have significantly improved the stability and efficacy of mRNA-based drugs, making them more commercially viable.

India's growing focus on biotechnology and personalized medicine further boosts the adoption of mRNA therapeutics. Researchers and biotech firms in the country are exploring mRNA's potential to address unmet medical needs, particularly in oncology and rare diseases, where conventional therapies have limitations. The flexibility of mRNA to encode various proteins also makes it a powerful platform for developing treatments for a broad spectrum of conditions.

Product Insights

Based on Indication, Infectious Diseases have emerged as the dominating segment in the India RNA Therapeutics Market in 2024, primarily driven by the success of RNA-based vaccines and therapeutics. The COVID-19 pandemic showcased the potential of RNA technology in combating infectious diseases, leading to increased investments and research in this field. India, with its vast population and high disease burden, faces ongoing challenges from conditions such as tuberculosis, hepatitis, and influenza, which further fuel the demand for RNA-based solutions.

Government initiatives promoting biotechnology advancements and public-private partnerships have played a crucial role in accelerating the adoption of RNA therapeutics. Research institutions and pharmaceutical companies are focusing on improving RNA delivery mechanisms, enhancing stability, and reducing costs, making these therapies more accessible. Moreover, increasing awareness among healthcare professionals and patients regarding the benefits of RNA-based treatments, such as their ability to provide targeted and rapid responses, is contributing to market growth.

Advancements in next-generation sequencing, bioinformatics, and nanotechnology are further supporting the expansion of this segment. As India continues to strengthen its healthcare infrastructure and regulatory frameworks, the RNA therapeutics market is expected to witness sustained growth, with infectious diseases remaining at the forefront of innovation and development.

Download Free Sample Report

Regional Insights

Based on Region, West India have emerged as the dominating region in the India RNA Therapeutics Market in 2024. West India is emerging as a dominant region in the RNA therapeutics market due to its robust biotechnology and pharmaceutical ecosystem, world-class infrastructure, and supportive government policies. States like Maharashtra and Gujarat are home to some of the largest pharmaceutical hubs in India, with cities like Pune, Mumbai, and Ahmedabad leading in research, manufacturing, and innovation. The presence of established pharmaceutical giants, biotech startups, and research institutions in these areas creates a fertile ground for the development and commercialization of advanced RNA therapeutics.

Additionally, West India benefits from a well-developed infrastructure for pharmaceutical manufacturing and exports. Gujarat, in particular, accounts for a significant share of India's pharmaceutical exports and houses advanced facilities for biologics and RNA-based drug production. The region's proximity to major ports further strengthens its export capabilities, enabling faster delivery of RNA-based products to global markets.

Recent Development

• In March 2025, TechInvention Lifecare signed a strategic collaboration with Belgium-based Quantoom Biosciences during the Belgian Economic Mission to India to accelerate development and manufacturing of RNA-based therapeutics and vaccines in the country. The deal brought Quantoom’s RNA N-Force toolbox to India and was positioned as a way to improve the accessibility, scalability, affordability, and environmental sustainability of RNA manufacturing, making it one of the clearest collaboration-led developments in India’s RNA therapeutics ecosystem.

• In March 2025, TechInvention said its partnership with Quantoom would support local production of mRNA and self-amplifying RNA vaccines at a planned Navi Mumbai facility expected to begin operations by October–November 2025. The company described the move as a milestone for democratizing RNA technology and enabling faster, more cost-effective vaccine development for India and other low- and middle-income countries, which gives the announcement clear significance as a manufacturing-capability breakthrough tied to RNA therapeutics.

• In January 2026, Knowmade reported that Indian biotech company PopVax emerged as a notable new filer in therapeutic mRNA intellectual property during Q4 2025, with five new patent applications. The report said PopVax’s growing pipeline and IP portfolio in mRNA-based therapeutics reflected India’s increasing role in next-generation biologics, making this a meaningful innovation signal because patent activity often precedes deeper product development and commercialization in advanced therapy platforms.

• In March 2026, PopVax said its mRNA-LNP COVID-19 vaccine candidate PVX-001 had received regulatory clearance from CDSCO and Telangana’s state regulator to manufacture phase-appropriate GMP batches of formulated bulk substance, including RNA synthesis and lipid nanoparticle encapsulation. This was a notable breakthrough for India’s RNA therapeutics field because it indicated that an Indian company had moved beyond early platform claims into regulator-cleared GMP manufacturing readiness for an in-house mRNA candidate, strengthening the country’s position in end-to-end RNA product development.

Key Market Players

• Pfizer Limited
• Novartis AG
• Sanofi S.A.
• Biocon Ltd Company
• Gennova Biopharmaceuticals Ltd.
• Cipla Limited
• Dr. Reddy's Laboratories
• Sun Pharmaceutical Industries Ltd.
• Bharat Biotech
• Serum Institute of India

Report Scope

In this report, the India RNA Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India RNA Therapeutics Market, By Product:

o   Vaccines

o   Drugs

• India RNA Therapeutics Market, By Type:

o   mRNA Therapeutics

o   RNA Interference (RNAi) Therapeutics

o   Antisense Oligonucleotide (ASO) Therapeutics

o   Others

• India RNA Therapeutics Market, By Indication:

o   Infectious Diseases

o   Rare Genetic Diseases/Hereditary Diseases

o   Other

• India RNA Therapeutics Market, By End User:

o   Hospitals and Clinics

o   Research Settings

• India RNA Therapeutics Market, By Region:

o   East India

o   West India

o   North India

o   South India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India RNA Therapeutics Market.

Available Customizations:

India RNA Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

India RNA Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]